BIOAFFINITY TECHNOLOGIES
BioAffinity Technologies applies experience, intelligence and creativity to the global fight against cancer. We know that by unlocking our personal potential, we make discoveries that give others an opportunity to live longer and more enjoyable lives. Our commitment is to continual scientific exploration, transparency and collaboration, and the development and commercialization of safer, more effective cancer treatments and patient-friendly tests that accurately diagnose early-stage cancer.
BIOAFFINITY TECHNOLOGIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
San Antonio, Texas, United States
Country:
United States
Website Url:
http://www.bioaffinitytech.com
Total Employee:
11+
Status:
Active
Contact:
(210)698-5334
Email Addresses:
[email protected]
Total Funding:
9.15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Employees Featured
Investors List
Run Business Solutions
Run Business Solutions investment in Seed Round - BioAffinity Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-14 | bioAffinity Technologies Announces Xavier T. Reveles Promoted to Vice President of Operations |
Official Site Inspections
http://www.bioaffinitytech.com Semrush global rank: 5.86 M Semrush visits lastest month: 1.42 K
- Host name: 183.51.230.35.bc.googleusercontent.com
- IP address: 35.230.51.183
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "BioAffinity Technologies"
bioAffinity Technologies, Inc. (BIAF)
Jun 20, 2024 [email protected]. Investor Relations. Julie Anne Overton Director of Communications 3300 Nacogdoches Road Suite 216 San Antonio, TX 78217 T: 210-698-5334 [email protected]. Transfer Agent. VStock …See details»
Home - bioAffinity Technologies
CyPath ® Lung is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company, as a Laboratory Developed Test (LDT).. CyPath ® Lung is a non-invasive test that assists clinical decision-making in lung cancer …See details»
Company Profile for bioAffinity Technologies, Inc.
Jun 10, 2020 bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and …See details»
Company Information :: bioAffinity Technologies, Inc.
[email protected]. Company Contact bioAffinity Technologies, Inc. 3300 Nacogdoches Road Suite 216 San Antonio, TX 78217 T: 210-698-5334 [email protected]. Email Alerts; Contacts; RSS News Feed Phone …See details»
BioAffinity Technologies - Crunchbase Company Profile …
Contact Email [email protected] Phone Number (210)698-5334 BioAffinity Technologies applies experience, intelligence and creativity to the global fight against cancer, the company addresses the need for noninvasive diagnosis of …See details»
Company Profile for bioAffinity Technologies, Inc.
Jun 10, 2020 Company: bioAffinity Technologies, Inc. Headquarters Address: 22211 W I-10, Suite 1206 San Antonio, TX 78257 Main Telephone: 5054009747See details»
Company Profile for bioAffinity Technologies, Inc. - BioSpace
Jun 10, 2020 Company: bioAffinity Technologies, Inc. Headquarters Address: 22211 W I-10, Suite 1206. San Antonio, TX 78257. Main Telephone: 5054009747. Website: www ...See details»
bioAffinity Technologies, Inc. (BIAF) Company Profile & Overview ...
Jan 3, 2025 22211 West Interstate 10, Suite 1206 San Antonio, Texas 78257 United StatesSee details»
bioAffinity Technologies
Dec 13, 2024 BioAffinity Technologies was founded in 2000. Our founding team integrated biotechnology and pharmaceutical development technologies combined with novel microfluidic platforms, advanced drug delivery concepts, and smart polymer materials to develop new opportunities in personalized medicine and oral drug delivery.See details»
bioAffinity Technologies - LinkedIn
BioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Company’s first product, CyPath® Lung, is a ...See details»
bioAffinity Technologies Names J. Michael Edwards as Chief …
Oct 10, 2024 [email protected]. Investor Relations Dave Gentry RedChip Companies Inc. 1-800-RED-CHIP (733-2447) or 407-491-4498 [email protected]. Categories. Articles (25) Events (38) News (50) Press Releases (103) Publications (17) Recent Posts. bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 November 14, 2024;See details»
Board of Directors :: bioAffinity Technologies, Inc. (BIAF)
In addition, Mr. Girgenti is Vice Chairman of the Board of Governors for the Mt. Sinai Hospital Prostate Disease and Research Center in New York City, and is on the Board of Directors for the Jack Martin Fund, a Mt. Sinai Hospital affiliated …See details»
bioAffinity Technologies Appoints New Chief Science Officer to ...
Nov 4, 2024 Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the …See details»
bioAffinity Technologies Appoints New Chief Science Officer to ...
Nov 4, 2024 bioAffinity Technologies Julie Anne Overton Director of Communications [email protected] Investor Relations Dave Gentry RedChip Companies Inc. 1-800-RED …See details»
bioAffinity Technologies Set for Continued Expansion in 2025
Dec 12, 2024 [email protected] Investor Relations Dave Gentry RedChip Companies Inc. 1-800-RED-CHIP (733-2447) or 407-491-4498 [email protected]. Source: bioAffinity …See details»
bioAffinity Technologies Presents Proprietary Cancer Therapeutic ...
Dec 1, 2022 bioAffinity reports on a potential therapeutic approach that kills cancer cells without harm to normal cells. SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. …See details»
bioAffinity Technologies Set for Continued Expansion in 2025
Dec 12, 2024 Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues SAN ANTONIO, TX (Dec. 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a …See details»
News & Articles - bioAffinity Tech
The CyPath ® Lung Flow Cytometry Test is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company, as a Laboratory Developed Test (LDT).. CyPath ® Lung is …See details»
bioAffinity Technologies Reports 217% Sales Growth in Second …
Jul 9, 2024 Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices . SAN ANTONIO, TX (July 9, 2024) – bioAffinity …See details»